Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

5 Stocks That Have Massive Upside According to Analysts

analysts ratings stocks

Analyst ratings are not perfect, but they're one of the better ways for investors to forecast future stock price movement. Here are five stocks that analysts believe have massive upside for patient, long-term investors.  

I found these stocks using the MarketBeat Analyst Ratings Screener tool. This is an excellent way to help you find stocks that are getting upgrades in the sectors and/or price ranges that fit your investment style. 

The Comeback Story is Gaining Steam 

Amazon.com, Inc. (NASDAQ: AMZN) stock is up 49% in 2023. Despite that surge, the stock is "only" up 6.75% in the last 12 months and has fallen back in the recent market sell-off. That just illustrates how lousy investor sentiment was in AMZN stock in 2022.  

It wasn't without reason. The company's earnings were down sharply, and it wasn't just about normalization in the company's e-commerce business. There was a slowdown in the company's Amazon Web Services (AWS) business as well.  

Some investors were also concerned that Amazon would be late to the artificial intelligence (AI) party. That may be true, but its recent announcement of an investment of up to $4 billion in Anthropic. This puts Amazon squarely into the generative AI conversation. It also provides an outlet for Amazon's Trainium and Inferentia chips, which Anthropic will use to build future large language models.  

All of that explains why AMZN stock has a Moderate Buy rating with a $161.30 price target that is 27.8% higher than its price as of this writing.  

This Stock is Worth Its Premium Valuation 

Its shares trade hands for over $1,800 per share. It has a forward P/E ratio of 42.3x. Despite all of that, Chipotle Mexican Grill, Inc. (NYSE: CMG) still appears to be an attractive buy. And CMG stock looks slightly oversold, with the stock down 12% in the last three months. 

The company continues to post higher year-over-year revenue and earnings. However, in its most recent quarter, it missed slightly on analysts' revenue expectations. That gave investors a reason to take a little profit. But the long-term story hasn't changed. Analysts still give the stock a Moderate Buy rating with a price target that is 19% higher than its current price. CMG stock remains a Buy.  

Analysts Continue to Buy This Oversold Stock 

Even dollar stores are not immune to inflationary pressures. In its earnings report for fiscal year (FY)2023, Dollar General (NYSE: DG) forecast slower sales for the rest of the year as consumers continue to pull back on discretionary spending.  

Not surprisingly, DG stock has been severely punished; it's down 57% in 2023. However, institutional investors (i.e., the smart money) still own 90% of the company's stock, and buyers continue to outnumber sellers. So even though analysts give Dollar General a consensus Hold, they have a price target that shows a 48% upside.  

Dollar General's business model puts its stores in predominantly rural areas that are not near big box stores. That makes them a lifeline for many consumers looking to find low-priced items without traveling far. And the company continues to launch new stores. 

With DG stock trading near its 52-week low, it looks like a great time to pick up some inexpensive shares.  

Short-Term Pain May be Worth Enduring 

When you're looking at taking a long position in any stock, a couple of years is a relatively short time. T-Mobile US, Inc. (NASDAQ: TMUS) is one of the leading global telecommunication companies. Earnings are up even as revenue is down, but investors still can't seem to get excited about TMUS stock. 

There's a reason for that. SoftBank (OTCMKTS: SFTBY) was the majority shareholder in Sprint. When T-Mobile merged with Sprint, SoftBank agreed to forfeit 48.8 million TMUS shares. However, under the terms of the merger, SoftBank can reclaim those shares if T-Mobile's stock price is over $150 for 45 days between 2022 and 2025.  

Sure enough, every time TMUS stock has cracked the $150 mark, the sell-off begins. That's likely to continue in the short term. Investors also aren't that excited about the company's dividend announcement as it implies that management believes the stock is fairly valued.  

Nevertheless, with inflation on the rise, the dividend gives long-term investors an incentive to hold TMUS stock. And with mobile phones being a relatively NASDAQ: TMUS">recession-proof item, patience is likely to be rewarded.  

Investors May be Missing the Catalyst for this Pharmaceutical Stock 

Pfizer, Inc. (NYSE: PFE) stock is down 37% in 2023, and the drop is even more pronounced since hitting an all-time high in December 2021. The conventional wisdom supports the pullback due to the normalization of the company's Covid-19-related products.  

But that may be missing the bigger picture. First, the company's acquisition of Seagen, Inc. (NASDAQ: SGEN) is likely to go through over the objection of some regulators. This will enhance Pfizer's oncology portfolio. And even without Seagen, the company has 19 drug candidates in its pipeline that are expected to be approved in the next 18 months.  

Analysts are seeing this. The consensus rating is Hold, but the price target is 44% higher than the current PFE stock price, which is around $32 as of this writing.  

Of the stocks on this list, Pfizer is still projecting that its earnings will decline slightly in the next 12 months. That may put pressure on PFE stock. However, building a position now is likely to pay off in years to come.  

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.